ViroGates announces revised financial guidance for 2026

BIRKERØD, DENMARK - ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, announces a revised financial guidance for 2026.

ViroGates now expects full-year revenue between DKK 6.5 and 8 million in 2026 (previously DKK 6 to 7 million), and maintains the previously guided EBIT at DKK -10 and -12 million.

The increase in expected full-year revenue is primarily attributable to ViroGates’ U.S. commercial partner, suPARbio^TM, taking delivery of milestone orders under the distribution agreement. These orders represent a significant volume for suPARbio™ to bring to market, and the next important step will be converting this stock into sales to end consumers.

The guidance also reflects that ViroGates is still transitioning its activities in other markets towards more scalable commercial channels, inducing some uncertainty regarding revenue in H2 2026. Operating costs are affected by staff changes and higher IVDR compliance costs, which will offset most of the contribution effect from the increased revenue.

ViroGates H1 report will be published on 20^th August 2026.

Jakob Knudsen, CEO of ViroGates, says: “Our revenue for the first half of 2026 reflects that our U.S. commercial partner, suPARbio^TM, has taken delivery of their milestone order under the distribution agreement – a tangible step in a partnership we strongly believe in. As previously mentioned, the U.S. is particularly well-structured for the introduction of a biomarker such as suPAR in preventive health and longevity screening, with a more mature clinical and laboratory infrastructure and a higher willingness to self-pay. We believe this market holds great potential for suPARnostic®.

We are staying closely engaged with suPARbio^TM as they work toward bringing the test to the U.S. longevity market at scale, and we look forward to reporting on progress as the roll-out to clients and clinics unfolds.”

For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]

Certified Advisor:
Västra Hamnen Corporate Finance AB
Per Lönn
Tel. (+46) 40 200 250 | Email: [email protected]

About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals to improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.

The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.